Skip to main
SOLV

Solventum Corporation (SOLV) Stock Forecast & Price Target

Solventum Corporation (SOLV) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 20%
Buy 40%
Hold 30%
Sell 0%
Strong Sell 10%

Bulls say

Solventum is a healthcare company with a strong track record of performance and growth in all business segments, supporting a Buy rating and a target price of $89. While the company has a potential for higher growth and has implemented changes to support margins and growth, its lower growth profile compared to peers may warrant a lower price-to-earnings multiple. Potential risks include challenges in establishing itself as a standalone company and potential selling pressure from institutional investors.

Bears say

Solventum is a healthcare company that operates in the competitive and highly regulated medical technology sector, with its three segments MedSurg, Dental Solutions, and Health Information Systems contributing to its majority revenue from the United States. While SOLV has maintained its revenue and operating margin outlook for 2026, timing delays and tailwinds may hinder its performance. Furthermore, SOLV's lower growth profile and tougher comps in FY26 compared to FY25 may impact its stock price. Risks to SOLV's ability to achieve its financial targets include potential decreases in global healthcare spending, competitive pressure, and new regulatory requirements from the FDA.

Solventum Corporation (SOLV) has been analyzed by 10 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 40% recommend Buy, 30% suggest Holding, 0% advise Selling, and 10% predict a Strong Sell.

This aggregate rating is based on analysts' research of Solventum Corporation and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Solventum Corporation (SOLV) Forecast

Analysts have given Solventum Corporation (SOLV) a Buy based on their latest research and market trends.

According to 10 analysts, Solventum Corporation (SOLV) has a Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $85.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $85.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Solventum Corporation (SOLV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.